Clinical trial · Interventional
Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure
Combined HLA-matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With Renal Failure
NCT00062621CI-TRIAL-00009298completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether a combined bone marrow and kidney transplant will be effective in treating stage II or greater multiple myeloma and associated kidney failure. This study will determine whether transplant rejection and the need for immunosuppressive drugs are decreased with this combined transplant approach.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Failure, Chronic | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Combined bone marrow and kidney transplant | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Remission status of multiple myeloma
- timeFrame
- Throughout study
- measure
- Renal allograft acceptance and ability to discontinue immunosuppressive therapy
- timeFrame
- Throughout study
Secondary outcomes (3)
- measure
- Graft vs. host disease (GVHD)
- timeFrame
- Throughout study
- measure
- Opportunistic infections
- timeFrame
- Throughouto study
- measure
- T-cell recovery and immune reconstitution
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * End-stage renal disease (ESRD) due to or in association with stage II or greater multiple myeloma * Participants in whom the development of ESRD is not due to the underlying myeloma will be included if they have evidence of active myeloma despite past treatment with standard therapies (e.g., prednisone, melphalan, high-dose radiation therapy with autologous stem cell transplantation) * On dialysis or have a creatinine clearance greater than 20 ml/min * HLA-matched or one of six HLA antigen-mismatched related donor Exclusion Criteria: * Compromised pulmonary, cardiac, or liver function * Active infection
References
Publications (0)
Data not yet available
No reference posted for this study.